{"ATC Code":"G04CB02","Abbreviation":"","Aliases":["Avodart","Avolve","GG-745","Duastride","GI 198745","GI-198745","Dutasterida","(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide","1H-Indeno[5,4-f]quinoline-7-carboxamide, N-[2,5-bis(trifluoromethyl)phenyl]-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-, (4aR,4bS,6aS,7S,9aS,9bS,11aR)-","alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide"],"Biological Half-Life":"The terminal elimination half-life of dutasteride is approximately 5 weeks at steady state. This long half-life accounts for the serum concentrations remaining detectable for up to 4 to 6 months after discontinuation of treatment.","CAS":"164656-23-9","CanonicalSMILES":"CC12CCC3C(C1CCC2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CCC5C3(C=CC(=O)N5)C","ChEBI":"CHEBI:521033","ChEMBL":"CHEMBL1200969","ChemicalClasses":["aminoindane"],"Dosing Info":[],"Drug Classes":"Benign Prostatic Hypertrophy Agents","Drug Indication":"Indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate gland to improve symptoms, and reduce the risk of acute urinary retention and the need for BPH-related surgery alone or in combination with [tamsulosin].","DrugClasses":[],"European Community (EC) Number":"638-758-5","FDA Pharmacological Classification":"O0J6XJN02I","Human Drugs":"Human drug -\u003e Prescription","IUPACName":"(1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide","InChI":"InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1","InChIKey":"JWJOTENAMICLJG-QWBYCMEYSA-N","MeSH Pharmacological Classification":"Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. (See all compounds classified as 5-alpha Reductase Inhibitors.)","Melting Point":"242-250","MolecularFormula":"C\u003csub\u003e27\u003c/sub\u003eH\u003csub\u003e30\u003c/sub\u003eF\u003csub\u003e6\u003c/sub\u003eN\u003csub\u003e2\u003c/sub\u003eO\u003csub\u003e2\u003c/sub\u003e","MolecularWeight":"528.5 g/mol","Pharmacodynamics":"Dutasteride is a synthetic 4-azasteroid compound that selectively inhibits both the type I and type II isoforms of steroid 5α-reductase, an intracellular enzyme that converts testosterone to 5α-dihydrotestosterone (DHT). Dutasteride works by reducing the levels of circulating DHT. It was also shown to reduce the size of the prostate gland, improve urinary flow, and symptoms of benign prostatic hyperplasia alone or in combination with tamsulosin. The effect of the reduction of DHT by dutasteride is dose-dependent, with the maximum effect observed within 1-2 weeks following initial administration.   After 1 and 2 weeks of daily dosing with dutasteride 0.5 mg, median serum DHT concentrations were reduced by 85% and 90%, respectively. The serum concentrations of DHT were maintained to be decreased by more than 90% in 85% of patients following 1 years' administration of oral dutasteride 0.5 mg/day. As evident from the clinical studies, dutasteride may also cause decreases in serum PSA in the presence of prostate cancer.","Physical Description":"Solid","PubChemId":6918296,"Record Description":["Dutasteride is an aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland. It has a role as an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a member of (trifluoromethyl)benzenes and a delta-lactam. It derives from a hydride of a 5alpha-androstane.","Dutasteride is an oral synthetic 4-azasteroid commonly marketed under the trade name Avodart. It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to enhance the therapeutic response. Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor. However, unlike finasteride, dutasteride is not yet indicated for the treatment of androgenic alopecia although it was demonstrated to be effective in several randomized, double-blind, placebo-controlled trials in androgenetic alopecia.","Dutasteride is a 5-alpha Reductase Inhibitor. The mechanism of action of dutasteride is as a 5-alpha Reductase Inhibitor.","Dutasteride is a 5-alpha reductase inhibitor used in the therapy of symptomatic benign prostatic hypertrophy. Dutasteride is associated with a low rate of transient serum aminotransferase elevations, but has yet to be linked to instances of clinically apparent acute liver injury.","Dutasteride is a synthetic 4-azasteroid compound. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5 alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5 alpha-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5 alpha-reductase isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also active in skin and the liver.","DUTASTERIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and has 3 approved and 8 investigational indications.","A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.","See also: Dutasteride; tamsulosin hydrochloride (component of).","Dutasteride is an aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland. It has a role as an EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor and an antihyperplasia drug. It is an aza-steroid, a member of (trifluoromethyl)benzenes and a delta-lactam. It derives from a hydride of a 5alpha-androstane."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Dutasteride"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q424760"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB01126"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/6918296"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.5293502.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1200969"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:521033"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=164656-23-9"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0015258"},{"name":"KEGG","url":"https://www.kegg.jp/entry/D03820"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/O0J6XJN02I"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID8046452"}],"Solubility":"Insoluble","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="142.527mm" version="1.2" viewBox="0 0 159.274 142.527" width="159.274mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#90E050" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="143.0" stroke="none" width="160.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="83.626" x2="82.013" y1="69.358" y2="54.204"/>
                  
            <line class="bond" id="mol1bnd2" x1="82.013" x2="68.805" y1="54.204" y2="61.824"/>
                  
            <line class="bond" id="mol1bnd3" x1="68.805" x2="55.597" y1="61.824" y2="54.204"/>
                  
            <line class="bond" id="mol1bnd4" x1="55.597" x2="55.597" y1="54.204" y2="38.964"/>
                  
            <line class="bond" id="mol1bnd5" x1="55.597" x2="68.805" y1="38.964" y2="31.344"/>
                  
            <line class="bond" id="mol1bnd6" x1="68.805" x2="82.013" y1="31.344" y2="38.964"/>
                  
            <line class="bond" id="mol1bnd7" x1="82.013" x2="82.013" y1="54.204" y2="38.964"/>
                  
            <line class="bond" id="mol1bnd8" x1="82.013" x2="96.542" y1="38.964" y2="34.29"/>
                  
            <line class="bond" id="mol1bnd9" x1="96.542" x2="105.483" y1="34.29" y2="46.584"/>
                  
            <line class="bond" id="mol1bnd10" x1="105.483" x2="96.542" y1="46.584" y2="58.878"/>
                  
            <line class="bond" id="mol1bnd11" x1="82.013" x2="96.542" y1="54.204" y2="58.878"/>
                  
            <line class="bond" id="mol1bnd12" x1="96.542" x2="101.269" y1="58.878" y2="73.366"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="102.647" x2="94.647" y1="73.657" y2="82.563"/>
                        
                <line x1="100.833" x2="92.833" y1="72.027" y2="80.934"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="94.647" x2="98.647" y1="82.563" y2="78.11"/>
                <line class="hi" stroke="#FF0D0D" x1="92.833" x2="96.833" y1="80.934" y2="76.4805"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="101.269" x2="112.87" y1="73.366" y2="75.817"/>
                  
            <line class="bond" id="mol1bnd15" x1="117.414" x2="120.908" y1="80.297" y2="91.004"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="135.826" x2="120.908" y1="94.159" y2="91.004"/>
                        
                <line x1="133.945" x2="121.781" y1="96.253" y2="93.681"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="135.826" x2="140.563" y1="94.159" y2="108.653"/>
                  
            <g class="bond" id="mol1bnd18">
                        
                <line x1="130.381" x2="140.563" y1="119.993" y2="108.653"/>
                        
                <line x1="129.508" x2="137.808" y1="117.316" y2="108.072"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd19" x1="130.381" x2="115.463" y1="119.993" y2="116.838"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="110.726" x2="115.463" y1="102.344" y2="116.838"/>
                        
                <line x1="113.481" x2="117.343" y1="102.925" y2="114.744"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="120.908" x2="110.726" y1="91.004" y2="102.344"/>
                  
            <line class="bond" id="mol1bnd22" x1="115.463" x2="105.281" y1="116.838" y2="128.178"/>
                  
            <line class="bond" id="mol1bnd23" x1="105.281" x2="95.841" y1="128.178" y2="119.702"/>
                  
            <line class="bond" id="mol1bnd24" x1="105.281" x2="97.378" y1="128.178" y2="136.979"/>
                  
            <line class="bond" id="mol1bnd25" x1="105.281" x2="114.212" y1="128.178" y2="136.197"/>
                  
            <line class="bond" id="mol1bnd26" x1="135.826" x2="146.008" y1="94.159" y2="82.819"/>
                  
            <line class="bond" id="mol1bnd27" x1="146.008" x2="154.94" y1="82.819" y2="90.839"/>
                  
            <line class="bond" id="mol1bnd28" x1="146.008" x2="153.888" y1="82.819" y2="74.043"/>
                  
            <line class="bond" id="mol1bnd29" x1="146.008" x2="136.569" y1="82.819" y2="74.344"/>
                  
            <line class="bond" id="mol1bnd30" x1="68.805" x2="68.806" y1="31.344" y2="16.104"/>
                  
            <line class="bond" id="mol1bnd31" x1="68.806" x2="55.61" y1="16.104" y2="8.482"/>
                  
            <line class="bond" id="mol1bnd32" x1="55.61" x2="42.411" y1="8.482" y2="16.097"/>
                  
            <line class="bond" id="mol1bnd33" x1="42.411" x2="42.404" y1="16.097" y2="31.336"/>
                  
            <line class="bond" id="mol1bnd34" x1="55.597" x2="42.404" y1="38.964" y2="31.336"/>
                  
            <line class="bond" id="mol1bnd35" x1="42.404" x2="29.203" y1="31.336" y2="38.951"/>
                  
            <g class="bond" id="mol1bnd36">
                        
                <line x1="16.008" x2="29.203" y1="31.325" y2="38.951"/>
                        
                <line x1="18.447" x2="29.204" y1="29.919" y2="36.135"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd37" x1="16.008" x2="16.014" y1="31.325" y2="16.085"/>
                  
            <g class="bond" id="mol1bnd38">
                        
                <line x1="16.014" x2="5.484" y1="17.493" y2="11.408"/>
                        
                <line x1="17.234" x2="6.704" y1="15.382" y2="9.297"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="5.484" x2="10.748999999999999" y1="11.408" y2="14.450499999999998"/>
                <line class="hi" stroke="#FF0D0D" x1="6.704000000000001" x2="11.969000000000001" y1="9.297" y2="12.339500000000001"/>
            </g>
                  
            <line class="bond" id="mol1bnd39" x1="16.014" x2="26.062" y1="16.085" y2="10.29"/>
                  
            <line class="bond" id="mol1bnd40" x1="42.411" x2="32.369" y1="16.097" y2="10.293"/>
                  
            <line class="bond" id="mol1bnd41" x1="42.404" x2="42.397" y1="31.336" y2="46.576"/>
                  
            <path class="atom" d="M93.345 84.701q.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.888q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM89.481 84.701q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm12" stroke="none"/>
                  
            <g class="atom" id="mol1atm13">
                        
                <path d="M118.121 78.966h-.72l-2.62 -4.066h-.029q.011 .238 .029 .595q.024 .357 .024 .732v2.739h-.565v-4.9h.714l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M122.427 78.966h-.619v-2.286h-2.512v2.286h-.613v-4.9h.613v2.072h2.512v-2.072h.619v4.9z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M93.188 120.446h-.613v-4.9h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.078z" id="mol1atm21" stroke="none"/>
                  
            <path class="atom" d="M94.346 141.967h-.613v-4.899h2.732v.542h-2.119v1.738h1.994v.542h-1.994v2.077z" id="mol1atm22" stroke="none"/>
                  
            <path class="atom" d="M115.867 140.809h-.613v-4.899h2.733v.542h-2.12v1.738h1.995v.542h-1.995v2.077z" id="mol1atm23" stroke="none"/>
                  
            <path class="atom" d="M156.595 95.451h-.614v-4.9h2.733v.542h-2.119v1.738h1.994v.542h-1.994v2.078z" id="mol1atm25" stroke="none"/>
                  
            <path class="atom" d="M155.437 73.929h-.613v-4.899h2.732v.541h-2.119v1.739h1.994v.542h-1.994v2.077z" id="mol1atm26" stroke="none"/>
                  
            <path class="atom" d="M133.915 75.087h-.613v-4.899h2.733v.541h-2.12v1.739h1.995v.541h-1.995v2.078z" id="mol1atm27" stroke="none"/>
                  
            <path class="atom" d="M5.078 8.457q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 8.457q-.0 .922 .387 1.458q.393 .53 1.22 .53q.84 -.0 1.221 -.53q.387 -.536 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm35" stroke="none"/>
                  
            <g class="atom" id="mol1atm36">
                        
                <path d="M31.157 10.921h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.476q-.006 -.262 -.006 -.483v-2.768h.578v4.9z" fill="#3050F8" stroke="none"/>
                        
                <path d="M31.02 5.459h-.619v-2.286h-2.513v2.286h-.613v-4.899h.613v2.072h2.513v-2.072h.619v4.899z" fill="#3050F8" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="112.87" x2="107.0695" y1="75.817" y2="74.5915"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="117.414" x2="119.161" y1="80.297" y2="85.6505"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="117.50391739255251" x2="119.161" y1="80.5725425077446" y2="85.6505"/>
            <line class="hi" id="mol1bnd23" stroke="#90E050" x1="95.841" x2="100.561" y1="119.702" y2="123.94"/>
            <line class="hi" id="mol1bnd24" stroke="#90E050" x1="97.378" x2="101.3295" y1="136.979" y2="132.57850000000002"/>
            <line class="hi" id="mol1bnd25" stroke="#90E050" x1="114.212" x2="109.7465" y1="136.197" y2="132.1875"/>
            <line class="hi" id="mol1bnd27" stroke="#90E050" x1="154.94" x2="150.474" y1="90.839" y2="86.82900000000001"/>
            <line class="hi" id="mol1bnd28" stroke="#90E050" x1="153.888" x2="149.948" y1="74.043" y2="78.43100000000001"/>
            <line class="hi" id="mol1bnd29" stroke="#90E050" x1="136.569" x2="141.2885" y1="74.344" y2="78.5815"/>
            <line class="hi" id="mol1bnd39" stroke="#3050F8" x1="26.062" x2="21.038" y1="10.29" y2="13.1875"/>
            <line class="hi" id="mol1bnd39" stroke="#3050F8" x1="26.062" x2="21.038" y1="10.29" y2="13.1875"/>
            <line class="hi" id="mol1bnd40" stroke="#3050F8" x1="32.369" x2="37.39" y1="10.293" y2="13.195"/>
            <line class="hi" id="mol1bnd40" stroke="#3050F8" x1="32.369" x2="37.39" y1="10.293" y2="13.195"/>
        </g>
          
    </g>
    
</svg>
","Title":"Dutasteride","UNII":"O0J6XJN02I","Wikidata":"Q424760","XLogP":5.4}